Revolution Medicines, Inc. 8-K

What Happened
Revolution Medicines, Inc. (RVMD) announced an equity offering entered into on April 14, 2026 and closed on April 16, 2026. The company sold 10,563,381 shares of common stock at $142.00 per share and granted the underwriters a 30‑day option for an additional 1,584,506 shares, which was exercised in full on April 15, 2026 (totaling 12,147,887 shares). Net proceeds from the equity offering are expected to be approximately $1,650.4 million after underwriting discounts, commissions and offering expenses. The equity offering was led by J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC and was registered on the company’s shelf (File No. 333-277640); a final prospectus supplement was filed April 15, 2026.

Concurrently, on April 14, 2026 the company entered into an underwriting agreement to offer $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033. That convertible note offering is expected to close on April 17, 2026, subject to customary closing conditions; the company said it will file a Form 8‑K reporting the closing and related documents after closing.

Key Details

• Equity sold: 10,563,381 shares at $142.00 per share; underwriter option for 1,584,506 shares exercised in full (total 12,147,887 shares).
• Net proceeds from equity offering: approximately $1,650.4 million (after fees and expenses).
• Convertible notes: $500 million aggregate principal, 0.50% coupon, due 2033; expected to close April 17, 2026 (subject to closing conditions).
• Lead underwriters: J.P. Morgan Securities LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC; legal opinion on issuance validity filed (Latham & Watkins LLP).

Why It Matters
The equity sale materially increases the company’s cash position by about $1.65 billion, which can support operations, R&D and other corporate needs. At the same time, issuing new shares immediately dilutes existing shareholders (12,147,887 shares issued in this transaction). The concurrent $500M convertible note offering brings low‑rate debt with potential future equity conversion, which could further affect capitalization if conversions occur. Investors should note the convertible offering was not closed as of the filing and remains subject to customary closing conditions.